Why the study?
The Venus-P valve was the first self-expanding valve used worldwide for TPVR in patients with severe PR, prompting the report of extended follow-up results from the prospective trial.
Does transcatheter pulmonary valve replacement using the Venus-P self-expanding valve maintain long-term function and safety in patients with severe pulmonary regurgitation?
Cohort (n=38)
Open-label
Yes
Does transcatheter pulmonary valve replacement using the Venus-P self-expanding valve maintain long-term function and safety in patients with severe pulmonary regurgitation?
The Venus-P self-expanding transcatheter pulmonary valve yields favorable clinical outcomes and freedom from valve dysfunction out to 5 years, though non-circular stent deformation is associated with an increased risk of stent fracture.
Background: The Venus-P valve was the first self-expanding valve used world-wide for transcatheter pulmonary valve replacement (TPVR) in patients with severe pulmonary regurgitation (PR). We intended to report the extended follow-up results from the prospective trial (No. NCT02590679). Methods: A total of 38 patients with severe PR (mean age 24.2 ± 13.2) were included. Follow-up data were obtained after implanted at 1, 6, and 12 months and yearly after. The frame geometry was assessed on post-implant computer tomography (CT) scanning by calculating the non-circularity [circularity ratio (minimum diameter/maximum diameter) < 0.9] and under-expansion [expansion ratio (derived external valve area/nominal external valve area) < 0.9). Adverse events (all-cause mortality, reintervention, valve dysfunction, stent fracture and endocarditis) were recorded. Results: All valves were implanted successfully with normal function at discharge. Geometric CT analysis showed under-expanded valve was detected in 22 patients (63%) and non-circular valve was seen in 16 patients (46%). During a median follow-up of 4.8 years (range 0.3–8.1), there were 1 death and 1 surgical explant, both resulting from endocarditis. Five-year freedom from valve dysfunction and stent fracture were 84.8% (95%CI 74.8–94.7) and 83.5% (95%CI 73.8–93.2). Endocarditis occurred in 3 patients at a median time of 7 months. Stent fracture was more common in patients with non-circularity stents. Conclusion: TPVR using Venus-P valve is associated with favorable outcomes at 5 years. Non-circular shapes in the valve level may have a higher risk of stent fracture.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted a cohort in Severe pulmonary regurgitation (n=38). Venus-P self-expanding transcatheter pulmonary valve was evaluated on Five-year freedom from valve dysfunction (95% CI 74.8-94.7).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: